Background: Herpes zoster (HZ) is an acute dermatological condition caused by the varicella-zoster virus. Its onset is characterized by severe pain, imposing significant physical and psychological burdens on patients. Acupuncture offers distinct advantages in treating acute herpes zoster and associated pain. However, the therapeutic efficacy of electroacupuncture for acute herpes zoster, its potential to reduce PHN incidence, and the role of biomarkers in predicting PHN incidence require further clinical validation. Methods: A total of 228 patients with acute herpes zoster will be recruited from 3 hospitals and randomly assigned to EA group or medication-alone group or sham acupuncture group in a 1:1:1 ratio, utilizing multicenter stratified block randomization. The trial will involve a 2 week treatment period, and a 3-month follow-up period. All variables will be evaluated at week 0, week 1, week 2, and on the 90th day after rash onset. All participants will continue antiviral medication treatment. Primary outcome is Numerical Rating Scale; secondary outcomes include herpes lesion crusting time, pain episodes within a 24-hour period, Hamilton Anxiety Scale, Hamilton Depression Scale, 36-Item Short Form Health Survey, changes of biomarkers (Erythrocyte sedimentation rate, C-reactive protein, Tumor Necrosis Factor-α, Interleukin-10, Substance P and neuropeptide Y) and PHN incidence rate. All adverse effects will be assessed during the trial. Conclusion: This study will elucidate the efficacy of electroacupuncture in treating acute herpes zoster, whether electroacupuncture can reduce the incidence of PHN, and the role of biomarkers in predicting the incidence of PHN.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
228
EA will be applied at Ashi points (sites of severe pain in herpetic lesions) and Jiaji points (EX-B2) on the affected side.All participants will undergo a 2-week treatment. Acupuncture will be performed thrice a week.A dense-disperse wave (2/100 Hz) will be used
non-penetrating placebo acupuncture
aciclovir will be administered for antiviral treatment (oral, 800 mg, 5 times daily for 7 days), and pregabalin for pain control (oral, 75 mg, twice daily throughout the trial)
the Third Affiliated Hospital of Zhejiang Chinese Medical University
Hangzhou, Zhejiang, China
RECRUITINGNumerical Rating Scale
an 11-point continuum ranging from 0 ('no pain') to 10 ('intolerable pain')
Time frame: week 0, 1, 2, 13
Pain episodes
Time frame: week0,1,2
Crusting Time
Time frame: week2
HAMA
Time frame: week0,1,2
HAMD
Time frame: week0,1,2
SF-36
Time frame: week0,1,2
ESR
Time frame: week0,1,2
CRP
Time frame: week0,1,2
TNF-α
Time frame: week0,1,2
IL-10
Time frame: week0,1,2
SP
Time frame: week0,1,2
NPY
Time frame: week0,1,2
PHN incidence
Time frame: week13
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.